Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | EZH2 | Q15910 | 8/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22401193 | 1.00 | GPR119 (0.45) | GPR119DDB1CRBNEZH2MMP13 | |
| SCHEMBL23672111 | 0.90 | GPR119 (0.45) | GPR119DDB1CRBNEZH2POLB | |
| SCHEMBL23672113 | 0.90 | GPR119 (0.45) | GPR119DDB1CRBNEZH2POLB | |
| SCHEMBL16344622 | 0.85 | EZH2 (0.43) | GPR119EZH2TLR9TLR8TLR7 | |
| SCHEMBL16344544 | 0.85 | EZH2 (0.51) | EZH2 | |
| SCHEMBL16376984 | 0.84 | EZH2 (0.49) | GPR119EZH2 | |
| SCHEMBL16493262 | 0.84 | EZH2 (0.49) | GPR119EZH2 | |
| SCHEMBL16347153 | 0.84 | EZH2 (0.49) | GPR119EZH2 | |
| SCHEMBL16347151 | 0.84 | EZH2 (0.49) | GPR119EZH2 | |
| SCHEMBL23672116 | 0.83 | GPR119 (0.42) | GPR119MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3707136-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3707136-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | TPMT, TET1, TET2 | GPR119 3613/4885DDB1 2663/4885CRBN 1011/4885 |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, TET2 | GPR119 3613/4885DDB1 2663/4885CRBN 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.